ArticleFrontiers in cardiovascular medicine2026
Development of a MACE risk prediction model based on CCTA-derived quantitative parameters: a proof-of-concept study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to identify factors influencing major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD) using quantitative parameters derived from coronary computed tomography angiography (CCTA), and to develop a nomogram-based risk prediction model. Methods: Clinical data from 280 CAD patients (May 2020-December 2023) were retrospectively analyzed. Based on 1-year follow-up, patients were divided into MACE and non-MACE groups. Baseline characteristics and CCTA-derived parameters were compared, and independent predictors were identified via multivariable logistic regression. A nomogram was constructed and internally validated using Bootstrap resampling, followed by external validation in an independent cohort of 288 patients. Results: Significant intergroup differences were observed in age, cardiac function grade, smoking history, hypertension history, CT-FFR, stenosis degree, plaque length, total vessel volume, minimal lumen area (MLA), fibrous and fibrofatty plaque volumes, plaque burden (PB), coronary artery calcium score (CACS), perivascular fat attenuation index (FAI), and myocardial mass/volume ratio (MAS) (all Conclusions: The nomogram based on CCTA-derived quantitative parameters demonstrates high predictive accuracy for MACE in CAD patients and may serve as a reliable clinical screening tool. However, given the short follow-up duration and predominance of soft endpoints (e.g., rehospitalization), these results should be interpreted cautiously regarding hard outcomes, and longer-term prospective studies are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.